President Donald Trump announced a new agreement with nine major pharmaceutical companies aimed at reducing prescription drug prices. The deal involves the companies selling outpatient drugs to state Medicaid programs at prices that match what they charge in foreign countries. In return, these manufacturers will be exempt from similar pricing requirements that apply to Medicare programs. The companies involved include Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB.
The agreements are part of a broader effort by the Trump administration to lower drug costs across the country, according to AOL. Trump has been working on similar deals with other pharmaceutical firms over the past year, including companies like Pfizer, Eli Lilly, and Novo Nordisk. The administration has also been promoting these agreements as a way to address concerns about drug affordability before the upcoming midterm elections, according to a report from The Hill.
While the exact financial impact of these deals remains unclear, some experts say it is difficult to assess their full effect without more information. The White House has not released the specific terms of the agreements, which has led to criticism from lawmakers and advocacy groups, USA Today reported. Some congressional Democrats have called the secretive nature of these deals misleading and lacking in real substance.
The companies involved in this deal are said to have negotiated with the administration. Trump has previously announced similar arrangements with 17 other drugmakers, as part of a larger push to lower prices on brand-name medications. The first such agreement was made with Pfizer in September 2025.
In addition to these pricing deals, the administration has also added more generic medications to a public website that helps consumers find lower-cost options. Senator Elizabeth Warren of Massachusetts has called for transparency by demanding that Health Secretary Robert F. Kennedy Jr. make public details of drug-pricing deals.
The administration’s approach to lowering drug prices includes a mix of voluntary agreements and public initiatives designed to increase competition in the market. The impact of these efforts on overall prescription drug costs remains uncertain due to limited public information about how the deals will be implemented.
Trump has emphasized that these agreements are part of a broader plan to bring down prices for American consumers. The companies participating in the deal have agreed to offer discounts on outpatient drugs through state Medicaid programs. Participation in these discounts by Medicaid programs is voluntary, giving states flexibility in how they choose to engage.
The administration has also been working on ways to help consumers access lower-cost medications through public websites and coupon systems.
IMAGE: Trump promised to bring sweeping political change, to create wealth, and to make America safe again in a speech that excited delegates on the fourth and final day of the convention. (A. Shaker/VOA). Photo: Ali Shaker/VOA / Wikimedia, taken 2016-07-21, Public domain